Sign in
Active, not recruitingPhase 2

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

Key facts

Who runs it
Translational Sciences, Inc.
Where
Augusta, Baltimore, Boston, Cleveland, Detroit, El Paso, Los Angeles, Philadelphia, Phoenix, Santa Barbara, Tucson, and Winston-Salem, United StatesSee the 13 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
64 people, planned
Started
24 May 2023
Expected to end
Nov 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • TS23
  • Placebo
Record updated
1 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Male or female subjects, age >18 years
  • PE involving a segmental or more proximal pulmonary artery confirmed by CTPA scan and with an onset of symptoms not more than 5 days prior to diagnosis
  • Subject is hemodynamically stable with a systolic blood pressure (SBP) >90 mm Hg
  • Subject has evidence of RV dysfunction as indicated by a right ventricular-to-left ventricular (RV/LV) diameter ratio > 0.9 on CTPA scan (measuring the minor axis of the right and left ventricle in the transverse plane), prior to the initiation of study drug administration

Who cannot take part

  • Subjects for whom thrombolytic therapy or thrombectomy is planned; or subjects with history of administration of thrombolytic agents within the previous 4 days
  • Subjects receiving ≥ 48 hours of therapeutic doses of heparin or low molecular weight heparin (LMWH) or other anticoagulant therapy immediately prior to randomization
  • Subjects with contraindications to SOC therapies such as unfractionated heparin or LMWH or oral anticoagulant, or any of the excipients (including study drug excipients)
  • Subjects who are considered at very high risk of bleeding:; Known coagulation disorder with history of pathologic bleeding tendencies; Subjects with prior intracranial hemorrhage, known arteriovenous malformation or aneurysm of the brain, or evidence of active bleeding; Subjects with a history of major surgery, clinically significant head trauma (in the opinion of the Principal Investigator), or stroke in the past 3 months prior to randomization; Subjects with uncontrolled hypertension defined as SBP ≥180 mm Hg and/or diastolic BP (DBP); ≥110 mm Hg at randomization; Subjects requiring concomitant dual antiplatelet therapy
  • Female subjects of child bearing potential with a positive pregnancy test or who are lactating, or unwilling to use highly effective methods of contraception. Highly effective methods of birth control include combination hormonal therapy (estrogen and progresterone), contraceptives administered orally, intravaginally or transdermally, progesterone-only contraceptives administered orally, by injection or implantation, use of an intrauterine device (IUD), intrauterine hormone- releasing system (IUS), bilateral tubal occlusion, partner vasectomy or sexual abstinence
  • Subjects currently participating in another investigational study or who have participated in an investigational drug study within 30 days (or longer depending on the half-life of the investigational drug; should allow at least five half-life of the investigational drug) prior to randomization
  • Subjects with known history of testing positive for Hepatitis B antigen or Hepatitis C antibody
  • Subjects with known history of testing positive for the human immunodeficiency virus (HIV)
  • Subjects with Creatinine Clearance (CrCL) < 30 mL/min or serum creatinine ≥ 2.5 mg/dL
  • Subjects with hemoglobin < 8.0 g/dL
  • Subjects with a platelet count < 100,000/µL
  • Subjects with acute or persistent hepatitis or diagnosed active liver disease or with elevation of liver enzymes: Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 x upper limit of normal (ULN)
  • Subjects with life-expectancy < 6 months

Where in United States

  • Wellstar MCG Health Medical CenterAugusta, United States
  • Lifebridge HealthBaltimore, United States
  • Tuft University HospitalBoston, United States
  • Cleveland ClinicCleveland, United States
  • Fairview HospitalCleveland, United States
  • Henry Ford HospitalDetroit, United States
  • Texas Tech University Health Sciences Center at El PasoEl Paso, United States
  • Cedars-Sinai Medical CenterLos Angeles, United States
  • Temple University HospitalPhiladelphia, United States
  • Banner University Medical CenterPhoenix, United States
  • Cottage HospitalSanta Barbara, United States
  • Banner University Medical Center - TucsonTucson, United States
  • Wake Forest University/Atrium Health's Carolinas Medical CenterWinston-Salem, United States

About the trial

What the trial wants to find out

Phase II trial of TS23

The 4 groups in the trial

  • PlaceboPlacebo, for comparison

    Placebo + standard of care (SOC) anticoagulation

  • Low dose TS23Treatment being tested

    TS23 low dose + SOC anticoagulation

    Treatment: TS23

  • Intermediate dose TS23Treatment being tested

    TS23 medium dose + SOC anticoagulation

    Treatment: TS23

  • Higher dose TS23Treatment being tested

    TS23 highest dose + SOC anticoagulation

    Treatment: TS23

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism
Publications
Record updated
1 July 2026